Literature DB >> 11701443

Ca(2+)-sensing receptor expression and PTHrP secretion in PC-3 human prostate cancer cells.

J L Sanders1, N Chattopadhyay, O Kifor, T Yamaguchi, E M Brown.   

Abstract

Prostate cancer metastasizes frequently to bone. Elevated extracellular calcium concentrations ([Ca(2+)](o)) stimulate parathyroid hormone-related protein (PTHrP) secretion from normal and malignant cells, potentially acting via the [Ca(2+)](o)-sensing receptor (CaR). Because prostate cancers produce PTHrP, if high [Ca(2+)](o) stimulates PTHrP secretion via the CaR, this could initiate a mechanism whereby osteolysis caused by bony metastases of prostate cancer promotes further bone resorption. We investigated whether the prostate cancer cell lines LnCaP and PC-3 express the CaR and whether polycationic CaR agonists stimulate PTHrP release. Both PC-3 and LnCaP prostate cancer cell lines expressed bona fide CaR transcripts by Northern analysis and RT-PCR and CaR protein by immunocytochemistry and Western analysis. The polycationic CaR agonists [Ca(2+)](o), neomycin, and spermine each concentration dependently stimulated PTHrP secretion from PC-3 cells, as measured by immunoradiometric assay, with maximal, 3.2-, 3.6-, and 4.2-fold increases, respectively. In addition, adenovirus-mediated infection of PC-3 cells with a dominant negative CaR construct attenuated high [Ca(2+)](o)-evoked PTHrP secretion, further supporting the CaR's mediatory role in this process. Finally, pretreating PC-3 cells with transforming growth factor (TGF)-beta(1) augmented both basal and high [Ca(2+)](o)-stimulated PTHrP secretion. Thus, in PTHrP-secreting prostate cancers metastatic to bone, the CaR could initiate a vicious cycle, whereby PTHrP-induced bone resorption releases [Ca(2+)](o) and TGF-beta stored within bone, further increasing PTHrP release and osteolysis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11701443     DOI: 10.1152/ajpendo.2001.281.6.E1267

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  34 in total

Review 1.  [Physical activity for primary prevention of prostate cancer. Possible mechanisms].

Authors:  H C Heitkamp; I Jelas
Journal:  Urologe A       Date:  2012-04       Impact factor: 0.639

2.  Calcium intake, polymorphisms of the calcium-sensing receptor, and recurrent/aggressive prostate cancer.

Authors:  Moritz Binder; Irene M Shui; Kathryn M Wilson; Kathryn L Penney; Lorelei A Mucci; Adam S Kibel
Journal:  Cancer Causes Control       Date:  2015-09-25       Impact factor: 2.506

3.  GPRC6A regulates prostate cancer progression.

Authors:  Min Pi; L Darryl Quarles
Journal:  Prostate       Date:  2011-06-16       Impact factor: 4.104

4.  Calcium-sensing receptor stimulation induces nonselective cation channel activation in breast cancer cells.

Authors:  Yassine El Hiani; Ahmed Ahidouch; Morad Roudbaraki; Stéphanie Guenin; Gérard Brûlé; Halima Ouadid-Ahidouch
Journal:  J Membr Biol       Date:  2006-10-14       Impact factor: 1.843

5.  Prognostic significance of calcium-sensing receptor in breast cancer.

Authors:  Xiaoyan Li; Li Li; Meena S Moran; Liyu Jiang; Xiangnan Kong; Hongyu Zhang; Xin Zhang; Bruce G Haffty; Qifeng Yang
Journal:  Tumour Biol       Date:  2014-03-01

Review 6.  The role of the calcium-sensing receptor in bone biology and pathophysiology.

Authors:  T A Theman; M T Collins
Journal:  Curr Pharm Biotechnol       Date:  2009-04       Impact factor: 2.837

7.  Serum calcium and incident and fatal prostate cancer in the National Health and Nutrition Examination Survey.

Authors:  Halcyon G Skinner; Gary G Schwartz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-09       Impact factor: 4.254

Review 8.  Targeting bone physiology for the treatment of metastatic prostate cancer.

Authors:  Karen A Autio; Michael J Morris
Journal:  Clin Adv Hematol Oncol       Date:  2013-03

9.  Prostate cancer and osteoporosis.

Authors:  Stephen P Tuck; Birgit Hanusch; Julie Walker; Harish K Datta
Journal:  Curr Osteoporos Rep       Date:  2013-03       Impact factor: 5.096

10.  The calcimimetic R-568 induces apoptotic cell death in prostate cancer cells.

Authors:  Huaifu Li; Guofeng Ruan; Zhijun Li; Ziwei Liu; Xiaoqing Zheng; Hao Zheng; Guangming Cheng; Benyi Li; Ming Zhan
Journal:  J Exp Clin Cancer Res       Date:  2009-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.